The 2019 ASCCP Management Guidelines – An Evolving Approach to Risk Assessment and Patient Management.

Jaime Rice2020-07-01T20:11:11-04:00June 29th, 2020|

Sana O. Tabbara MD1* and Ritu Nayar MD2*#^*American Society of Cytopathology Representatives# Cytopathology Education and Technology Consortium Representative^ Pathologist on ASCCP Guidelines Steering CommitteeAffiliationThe George Washington University, Department of Pathology, Washington, District of ColumbiaNorthwestern University, Feinberg School of Medicine, Department of Pathology and Northwestern Memorial Hospital, Chicago, IllinoisThe 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening tests and Cancer Precursors were published on April 2, 2020 in the Journal of Lower Genital Tract Diseases.1 Following a Memorandum of Understanding between the ASCCP and National Cancer Institute (NCI) in January 2017, seven (7) working groups with representation from stakeholders across medical professional societies, patient advocacy groups and federal agencies were tasked with updating the guidelines following a kickoff meeting in February 2018. The focus was organized around the goal of establishing consensus Clinical Action Thresholds rather than specific test outcomes using analysis and follow-up from large data [...]